EB
APLS

Eastern Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Eastern Bank’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$173K – 1013
2025
Q2 		$173K Sell
10,000
-11,500
-53% -$213K ﹤0.01% 375
2025
Q1 		$470K Hold
21,500
– – 0.01% 272
2024
Q4 		$686K Buy
21,500
+10,000
+87% +$301K 0.01% 242
2024
Q3 		$332K Buy
+11,500
New +$426K 0.01% 322

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Eastern Bank's APLS Position: Q3 2025 in Review

Eastern Bank sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 10,000 shares — an estimated $173K sold.

Eastern Bank first reported a position in APLS in Q3 2024 and held it in 4 quarters. The position peaked at $686K in Q4 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Eastern Bank reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Eastern Bank sold 10,000 Apellis Pharmaceuticals shares in Q3 2025, an estimated $173K.
  • Eastern Bank first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Eastern Bank's Apellis Pharmaceuticals position peaked at $686K in Q4 2024.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Eastern Bank's 13F filing for Q3 2025, filed 27 Oct 2025.